43 50

Cited 0 times in

Effect of fenofibrate in 1113 patients at low-density lipoprotein cholesterol goal but high triglyceride levels: Real-world results and factors associated with triglyceride reduction

 Yeongmin Woo  ;  Jeong-soo Shin  ;  Chi-Young Shim  ;  Jung-Sun Kim  ;  Byeong-Keuk Kim  ;  Sungha Park  ;  Hyuk-Jae Chang  ;  Geu-Ru Hong  ;  Young-Guk Ko  ;  Seok-Min Kang  ;  Donghoon Choi  ;  Jong-Won Ha  ;  Myeong-Ki Hong  ;  Yangsoo Jang  ;  Sang-Hak Lee 
 PLoS One, Vol.13(10) : e0205006, 2018 
Journal Title
 PLoS One 
Issue Date
Fibrates are used in patients with dyslipidemia and high cardiovascular risk. However, information regarding drug response to fibrate has been highly limited. We investigated treatment results and factors associated with triglyceride reduction after fenofibrate therapy using large-scale real-world data. Patients with one or more cardiovascular risk factors, at low-density lipoprotein-cholesterol goal but with triglyceride level ≥150 mg/dL, and undergoing treatment with fenofibrate 135-160 mg for the first time were included in this retrospective observational study. The outcome variable was the percentage changes of TG levels. The achievement rate of triglyceride <150 mg/dL was additionally analyzed. Factors associated with treatment results were also analyzed. Among 2546 patients who were initially screened, 1113 patients were enrolled (median age: 61 years; male: 71%). After median follow-up of 4 months, the median change in triglyceride was -60%, and 49% of the patients reached triglyceride <150 mg/dL. After adjusting for confounding variables, female sex, non-diabetic status, coronary artery disease, lower baseline triglyceride, and no statin use were identified to be independently associated with achievement of triglyceride <150 mg/dL. Among them, female sex, non-diabetic status, and coronary artery disease were also related to median or greater percentage reduction of triglyceride. In conclusion, only half of the study patients reached triglyceride levels <150 mg/dL after real-world fenofibrate therapy. This study indicates that more attention is needed on some subgroups to obtain optimal triglyceride levels when treating with fenofibrate.
Files in This Item:
T201803563.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
강석민(Kang, Seok Min) ORCID logo https://orcid.org/0000-0001-9856-9227
고영국(Ko, Young Guk) ORCID logo https://orcid.org/0000-0001-7748-5788
김병극(Kim, Byeong Keuk) ORCID logo https://orcid.org/0000-0003-2493-066X
김중선(Kim, Jung Sun) ORCID logo https://orcid.org/0000-0003-2263-3274
박성하(Park, Sung Ha) ORCID logo https://orcid.org/0000-0001-5362-478X
심지영(Shim, Chi Young) ORCID logo https://orcid.org/0000-0002-6136-0136
이상학(Lee, Sang Hak) ORCID logo https://orcid.org/0000-0002-4535-3745
장양수(Jang, Yang Soo) ORCID logo https://orcid.org/0000-0002-2169-3112
장혁재(Chang, Hyuck Jae) ORCID logo https://orcid.org/0000-0002-6139-7545
최동훈(Choi, Dong Hoon) ORCID logo https://orcid.org/0000-0002-2009-9760
하종원(Ha, Jong Won) ORCID logo https://orcid.org/0000-0002-8260-2958
홍그루(Hong, Geu Ru) ORCID logo https://orcid.org/0000-0003-4981-3304
홍명기(Hong, Myeong Ki) ORCID logo https://orcid.org/0000-0002-2090-2031
RIS (EndNote)
XLS (Excel)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.